Cascade Pharmaceuticals, Inc
13
3
6
6
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 13 trials
100.0%
+13.5% vs industry average
8%
1 trials in Phase 3/4
0%
0 of 6 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (13)
A Study of CS060380 Tablets in Patients With MASH and Obesity
Role: lead
CS0159 in Chinese Patients With PBC (Primary Biliary Cholangitis)
Role: lead
Study to Evaluate Safety, Tolerability and Pharmacokinetics of CS060304 in Healthy and Elevated LDL-C Subjects
Role: lead
CS0159 in Chinese Patients With PSC (Primary Sclerosing Cholangitis)
Role: lead
Trial of CS060380 Tablets for Non-alcoholic Steatohepatitis (NASH)
Role: lead
Drug Interaction and Food Effect Study of CS0159
Role: lead
A Study of CS0159 in Patients With PBC With Inadequate Response or Intolerance to UDCA
Role: lead
Study to Evaluate Safety, Tolerability and Pharmacokinetics of CS060380 in Healthy and Elevated LDL-C Subjects
Role: lead
A Study of the Pharmacokinetics and Safety of CS0159 in Subjects With Hepatic Injury
Role: lead
Study of [14C]CS0159 in China Healthy Subjects
Role: lead
A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of CS0159 in Subjects With NASH
Role: lead
Study to Evaluate Safety, Tolerability and Pharmacokinetics of CS0159 in Chinese Healthy Subjects
Role: lead
Study in Healthy Volunteers to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CS0159
Role: lead
All 13 trials loaded